SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001387131-22-001703
Filing Date
2022-02-11
Accepted
2022-02-11 17:03:47
Documents
2
Group Members
ATLAS VENTURE ASSOCIATES OPPORTUNITY I, L.P.ATLAS VENTURE ASSOCIATES OPPORTUNITY I, LLCATLAS VENTURE ASSOCIATES XI, L.P.ATLAS VENTURE ASSOCIATES XI, LLCATLAS VENTURE OPPORTUNITY FUND I, L.P.

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13G dawn-sc13g_021122.htm SC 13G 102310
2 EXHIBIT A - JOINT FILING AGREEMENT ex-a.htm EX-1 13605
  Complete submission text file 0001387131-22-001703.txt   117847
Mailing Address 400 TECHNOLOGY SQUARE 10TH FLOOR CAMBRIDGE MA 02139
Business Address 400 TECHNOLOGY SQUARE 10TH FLOOR CAMBRIDGE MA 02139 857-201-2700
Atlas Venture Fund XI, L.P. (Filed by) CIK: 0001708269 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G

Mailing Address 395 OYSTER POINT BLVD STE 217 SOUTH SAN FRANCISCO CA 94080-1930
Business Address 395 OYSTER POINT BLVD STE 217 SOUTH SAN FRANCISCO CA 94080-1930 206-913-4300
Day One Biopharmaceuticals, Inc. (Subject) CIK: 0001845337 (see all company filings)

IRS No.: 832415215 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-92582 | Film No.: 22622478
SIC: 2834 Pharmaceutical Preparations